DOD Biotech Public Company Limited reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was THB 537.16 million compared to THB 1,015.32 million a year ago. Revenue was THB 548.33 million compared to THB 1,018.35 million a year ago.

Net loss was THB 398.33 million compared to net income of THB 49.79 million a year ago. Basic loss per share from continuing operations was THB 0.84 compared to basic earnings per share from continuing operations of THB 0.58 a year ago. Diluted loss per share from continuing operations was THB 0.84 compared to diluted earnings per share from continuing operations of THB 0.58 a year ago.

Basic loss per share was THB 0.97 compared to basic earnings per share of THB 0.12 a year ago. Diluted loss per share was THB 0.97 compared to diluted earnings per share of THB 0.12 a year ago.